Clinical Trial Update: Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating nab-paclitaxel in patients with sensitive and refractory relapsed small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica | Conditions: Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN